Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15076 - 15100 of 15142 in total
PCO-371 is under investigation in clinical trial NCT02475616 (A Single Ascending Dose Study of PCO371 in Healthy Volunteers).
Investigational
ATX-101 (medical), sodium deoxycholate for subcutaneous injection, is being evaluated as a treatment for the reduction of localized fat deposits. This includes treatment of superficial lipomas (benign tumors of soft tissue composed of mature fat cells), fat deposits in the submental region of the face/neck, and localized fat deposits in...
Investigational
Matched Description: … of soft tissue composed of mature fat cells), fat deposits in the submental region of the face/neck, and
Cannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa.
Experimental
Investigational
Matched Categories: … Cannabinoids and similars …
Experimental
Matched Iupac: … -2-en-1-yl]amino}-3,4-dihydroxy-6-methyloxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl
Experimental
Matched Iupac: … 13R,14S,18S,19S)-8,13,18-tris[2-(C-hydroxycarbonimidoyl)ethyl]-3,14,19-tris[(C-hydroxycarbonimidoyl)methyl
An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas. This new concept of oncological immunotherapy consists of an attempt to trigger the immune system of the host...
Investigational
Matched Description: … To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow …
Experimental
Vet approved
Matched Iupac: … 'R,7aR)-6-{[(2S,3R,4R,5S,6R)-2-{[(2R,3S,4S,5S,6S)-6-[(2R,3aS,3'aR,6'R,7R,7'S,7aR,7'aR)-7'-acetyl-6'-methyl
PRLX 93936 is selectively toxic to cancer cells.
Investigational
XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.
Investigational
Carphenazine is an antipsychotic drug, used in hospitalized patients in the management of chronic schizophrenic psychoses.
Withdrawn
105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of this disease.
Investigational
ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
Investigational
NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
Investigational
Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).
Investigational
Sarconeos is an activator of the MAS receptor.
Investigational
REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Investigational
PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
Investigational
AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
Investigational
Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Investigational
Displaying drugs 15076 - 15100 of 15142 in total